Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to   be sent to the relevant issuer and to the FCA in Microsoft   Word format if possible)i
1a. Identity of the issuer or the underlying issuer of   existing shares to which voting rights are attachedii: AstraZeneca PLC
1b. Please indicate if the issuer is a non-UK   issuer  (please mark with an   "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please   mark the appropriate box or boxes with an "X")
An acquisition or disposal of   voting rights
An acquisition or disposal of   financial instruments
An event changing the breakdown of   voting rights
Other (please specify)iii: A change in   the total voting rights notified by AstraZeneca PLC on 2 April 2019. X
3. Details of person subject to the notification   obligationiv
Name Investor AB
City and country of registered   office (if applicable) Stockholm, Sweden
4. Full name of shareholder(s) (if   different from 3.)v
Name N/A
City and country of registered   office (if applicable) N/A
5. Date on which the threshold was crossed or reachedvi: 2 April 2019
6. Date on which issuer   notified (DD/MM/YYYY): 3 April 2019
7. Total positions of person(s) subject to the   notification obligation
%   of voting rights attached to shares (total of 8. A) %   of voting rights through financial instruments
  (total of 8.B 1 + 8.B 2)
Total   of both in % (8.A + 8.B) Total number of voting rights of   issuervii
Resulting situation on the date on   which threshold was crossed or reached 3.93% N/A 3.93% 1,311,755,099
Position of previous notification   (ifapplicable) 4.02% N/A 4.02%

 

8. Notified details of the resulting situation on the date   on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
  shares
ISIN code (if possible)
Number of voting rightsix % of voting rights
Direct(Art   9 of Directive 2004/109/EC) (DTR5.1) Indirect(Art   10 of Directive 2004/109/EC) (DTR5.2.1) Direct(Art   9 of Directive 2004/109/EC) (DTR5.1) Indirect(Art   10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary shares of $0.25 eachISIN - GB0009895292 51,587,810 N/A 3.93% N/A
SUBTOTAL 8. A 51,587,810 3.93%
B 1: Financial Instruments according to Art. 13(1)(a) of   Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
  date
x
Exercise/
  Conversion Period
xi
Number of voting rights that may   be acquired if the instrument isexercised/converted. % of voting rights
SUBTOTAL 8. B 1 N/A N/A
B 2: Financial Instruments with similar economic effect   according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
  date
x
Exercise/
  Conversion Period 
xi
Physical or cashsettlementxii Number of voting rights % of voting rights
SUBTOTAL 8.B.2 N/A N/A

 

9. Information in relation to the person subject to the   notification obligation (please mark theapplicable box with an "X")
Person subject to the notification   obligation is not controlled by any natural person or legal entity and does   not control any other undertaking(s) holding directly or indirectly an   interest in the (underlying) issuerxiii X
Full chain of controlled undertakings through which the   voting rights and/or the
  financial instruments are effectively held starting with the ultimate   controlling natural person or legal entityxiv(please add additional rows as necessary)
Namexv % of voting rights if it equals or   is higher than the notifiable threshold % of voting rights through   financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is   higher than the notifiable threshold
10. In   case of proxy voting, please identify:
Name of the proxy holder N/A
The number and % of voting rights held N/A
The date until which the voting rights will be held N/A
11. Additional informationxvi
This notification has been prepared using the total voting   rights figure of 1,311,755,099 ordinary shares as set out in the public   announcement made by AstraZeneca PLC on 2 April 2019.

 

Place of completion Stockholm, Sweden
Date of completion 3 April 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links